Table 5. Adverse events following PG2 treatment.
| Variable | CG (%) (N = 31) | TG (%) (N = 30) | χ2 | P value |
|---|---|---|---|---|
| Adverse event | 0.82 | 0.37 | ||
| No | 14 (45.17) | 18 (60.00) | ||
| Yes | 17 (54.84) | 12 (40.00) | ||
| headache | 0.20† | |||
| No | 26 (83.87) | 29 (96.67) | ||
| Yes | 5 (16.13) | 1 (3.33) | ||
| Cough/fever | 0.47† | |||
| No | 25 (80.65) | 27 (90.00) | ||
| Yes | 6 (19.35) | 3 (10.00) | ||
| Diarrhea/vomiting | 0.11† | |||
| No | 31 (100.00) | 27 (90.00) | ||
| Yes | 0 (0.00) | 3 (10.00) | ||
| Constipation | 0.11† | |||
| No | 27 (87.10) | 30 (100.00) | ||
| Yes | 4 (12.90) | 0 (0.00) | ||
| Skin puritis | 1.00† | |||
| No | 28 (90.32) | 27 (90.00) | ||
| Yes | 3 (9.68) | 3 (10.00) | ||
| Urinary problem | 0.20† | |||
| No | 26 (83.87) | 29 (96.67) | ||
| Yes | 5 (16.13) | 1 (3.33) |
CG: control group; TG: treatment group; independent test for continuous data; chi-squared test for categorical data; †Fisher’s exact test.